licensing

News

CSL joins forces with Alentis on claudin candidate

CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Novo turns to Hengrui for another oral obesity drug

Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.

News

MSD takes a $400m bite of SciBrunch's KRAS drug

MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

News

InnoCare and Eli Lilly logos over a handshake graphic in the background

Lilly forges $3.35bn alliance with China's InnoCare

Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.

CSL joins forces with Alentis on claudin candidate

Novartis taps China's Abogen for autoimmunity TCE

Novo turns to Hengrui for another oral obesity drug

MSD takes a $400m bite of SciBrunch's KRAS drug

Is the next generation of Chinese biotech ready to go global...

Lilly forges $3.35bn alliance with China's InnoCare

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

licensing

Editor's Picks